Samsung Biologics announced that it will accelerate the construction and completion of Plant 5, which will now be in operation by April 2025. The plant will add 180,000L capacity to Samsung Biologics’ capabilities, so it will maintain the world’s largest biomanufacturing capacity at 784,000L upon completion. Samsung Biologics CEO John Rim announced at BIO2023 that completion of the fifth plant was initially expected in September 2025.
This week Samsung Biologics and Pfizer announced a collaboration to manufacture biosimilars.